- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00729950
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
An Open-Label Pharmacokinetic and Safety Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Study Overview
Detailed Description
Group A: Six to 12 subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5 mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57, and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally, 6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10, 15, and 20 mg/kg.
Dose escalation from the 5 mg/kg cohort to the 7.5 mg/kg cohort will depend on the safety profile following a single dose of 5 mg/kg. Once all subjects are enrolled in the 5 mg/kg cohort and 4 weeks have elapsed since the sixth subject in the cohort has received the first infusion, dose escalation to the 7.5 mg/kg cohort may occur if ≤1 DLT has occurred in the 5 mg/kg cohort. Dose escalation to the 10 mg/kg cohort may occur 4 weeks after the sixth subject in the 7.5 mg/kg/dose cohort has received the first infusion (with ≤1 DLT). Dose escalation to the 15 and 20 mg/kg cohorts may occur 4 weeks after the sixth subject in the previous cohort has received the first infusion (with ≤1 DLT). Up to six additional subjects may be enrolled in the MTD dose cohort or in the 20 mg/kg dose cohort if MTD is not attained.
Group B: If single-dose administration of MDX-010 at 10 mg/kg is well tolerated (≤1 DLT in the cohort in Group A), then an additional 12 to 20 subjects will be enrolled and treated with MDX-010 at 10 mg/kg/dose administered on Days 1, 22, 43, and 64.
Subjects who respond to therapy will be followed until disease progression or a maximum of approximately 1 year. Subjects with a response of SD ≥ 3 months, PR, or CR to their initial treatment cycle who subsequently relapse may be eligible for retreatment with the same regimen or an alternate regimen considered to be more effective at the time of retreatment.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724-5024
- Arizona Cancer Center
-
-
California
-
Los Angeles, California, United States, 90033
- USC/Norris Comprehensive Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- Piedmont Oncology Specialists
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Portland Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject must have read, understood, and provided written informed consent and authorization in compliance with the Health Insurance Portability and Accountability Act (HIPAA) afer the nature of the study has been fully explained.
- Subject must be at least 18 years of age with a histologic diagnosis of unresectable Stage III or IV malignant melanoma (may include mucosal melanoma). Subjects with either stable or progressive malignancy will be permitted in the study. Classification of stable or progressive disease, to be recorded for all subjects, will be defined by the Response Evaluation Criteria in Solid Tumors (RECIST), as detailed in Appendix 3 and determined since last melanoma treatment. Subjects must have at least 1 site of measurable disease.
- At least 4 weeks since treatment (surgery, chemotherapy, radiation, or immuno- therapy) for melanoma and recovered from any serious toxicity experienced during treatment.
- Life expectancy of at least 18 weeks.
- Karnofsky Performance Status of at least 70%
Screening laboratory values must meet the following criteria:
- WBC ≥2500/μL
- ANC ≥1500/μL
- Platelets ≥100 x 10'/μL
- Hematocrit ≥30%
- Hemoglobin ≥10 g/dL
- Creatinine ≤2 mg/dL
- AST ≤2 x ULN*
- Bilirubin ≤1.0 x ULN*, (except subjects with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
- HIV negative
- HBsAg negative
- anti-HCV nonreactive. If reactive, subject must have a negative HCV RNA qualitative PCR.
- Unless definitely attributable to disease.
Exclusion Criteria:
- Any prior malignancy except for the following: adequately treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or any other cancer from which the subject has been disease-free for at least 5 years
- History of autoimmune disease (including uveitis and autoimmune inflammatory eye disease) prior to entrance into the study.
- Active infection requiring therapy, chronic active HBV or HCV, or confirmed reactivity with HIV tests.
- Tetanus booster immunization within 2 months of initial screening procedures, or a history of anaphylaxis or severe local reaction to the tetanus vaccine.
- Pregnant or nursing: it is not known what effect MDX-010 could have on the developing immune system of the fetus or infant, therefore, exposure in utero or via breast milk will not be allowed.
- Any underlying medical condition which, in the opinion of the principal investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events.
- Any concurrent medical condition requiring the use of systemic or topical corticosteroids or the use of immunosuppressive agents (e.g. cyclosporine and its analog, or chemotherapy agents). All corticosteroid use must have been discontinued at least 4 weeks prior to trial entry.
- Prior treatment with MDX-010 or any other anti-CTLA-4 monoclonal antibody.
- Evidence or history of significant cardiac, pulmonary, hepatic, renal, psychiatric or gastrointestinal disease that would make the administration of MDX-010 unsafe.
- Concurrent treatment with chemotherapy or other immunotherapy regimens (must be completed at least 4 weeks before Screening).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the safety and pharmacokinetic profile of single and multiple doses of MDX-010.
Time Frame: up to approximately 1 year
|
up to approximately 1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the clinical activity profile of single and multiple doses of MDX-010
Time Frame: up to aproximately one year.
|
up to aproximately one year.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Ipilimumab
Other Study ID Numbers
- MDX010-15
- CA184-001 (Other Identifier: BMS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Melanoma
-
National Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant MelanomaUnited States
-
Grupo Español Multidisciplinar de MelanomaGlaxoSmithKlineCompletedMalignant Melanoma Stage IV | Malignant Melanoma Stage IIIcSpain
-
Centre Hospitalier Universitaire de NiceUnknownMalignant Melanoma Stage III | Malignant Melanoma Stage IV
-
Hoffmann-La RocheCompletedMalignant Melanoma, CancerHungary
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsUnited States, South Africa, Croatia, Brazil, Egypt
-
Lynn E. Spitler, MDGenentech, Inc.; Celgene CorporationCompletedMetastatic Malignant MelanomaUnited States
-
National Cancer Institute (NCI)GlaxoSmithKline; Novartis PharmaceuticalsActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...United States
-
Steinar AamdalTerminatedMetastatic Malignant MelanomaNorway
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsBelgium, Spain, Germany, Netherlands, Finland
-
Eli Lilly and CompanyCompletedMetastatic Malignant MelanomaUnited States
Clinical Trials on MDX-010
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompletedNeoplasm Metastasis | Prostate CancerUnited States
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbMedarexCompletedHuman Immunodeficiency Virus (HIV)United States
-
Center Trials & TreatmentBioGene Pharmaceutical Inc.No longer availableGlioblastoma | Glioma of BrainBosnia and Herzegovina, Albania, Bulgaria, Croatia, Romania, Russian Federation, Serbia, Switzerland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHepatocellular Carcinoma | Resectable Hepatocellular CarcinomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedPhase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for MelanomaRecurrent Melanoma | Stage IV Melanoma | Tumors Metastatic to BrainUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of... and other collaboratorsActive, not recruitingPathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8United States
-
Bristol-Myers SquibbActive, not recruitingAdvanced or Metastatic Solid TumorsUnited States, Germany, Spain, United Kingdom, Italy, Canada, Denmark, Finland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMyelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation RecipientUnited States